• <tr id='SMVEXI'><strong id='SMVEXI'></strong><small id='SMVEXI'></small><button id='SMVEXI'></button><li id='SMVEXI'><noscript id='SMVEXI'><big id='SMVEXI'></big><dt id='SMVEXI'></dt></noscript></li></tr><ol id='SMVEXI'><option id='SMVEXI'><table id='SMVEXI'><blockquote id='SMVEXI'><tbody id='SMVEXI'></tbody></blockquote></table></option></ol><u id='SMVEXI'></u><kbd id='SMVEXI'><kbd id='SMVEXI'></kbd></kbd>

    <code id='SMVEXI'><strong id='SMVEXI'></strong></code>

    <fieldset id='SMVEXI'></fieldset>
          <span id='SMVEXI'></span>

              <ins id='SMVEXI'></ins>
              <acronym id='SMVEXI'><em id='SMVEXI'></em><td id='SMVEXI'><div id='SMVEXI'></div></td></acronym><address id='SMVEXI'><big id='SMVEXI'><big id='SMVEXI'></big><legend id='SMVEXI'></legend></big></address>

              <i id='SMVEXI'><div id='SMVEXI'><ins id='SMVEXI'></ins></div></i>
              <i id='SMVEXI'></i>
            1. <dl id='SMVEXI'></dl>
              1. <blockquote id='SMVEXI'><q id='SMVEXI'><noscript id='SMVEXI'></noscript><dt id='SMVEXI'></dt></q></blockquote><noframes id='SMVEXI'><i id='SMVEXI'></i>

                您的当前位置: 首页 科研开发

                临床试验

                1、临床试验介绍:据国家癌症中心2011年数据显示,肝癌是我国高发病率的癌种之一,在发病率前十的肿瘤中位列第五,死亡率位列第三。肝癌术后......

                详情

                精准医疗

                精准医疗是肿瘤临床治疗的大势所趋,是通过基因组学、蛋白质组学,生物信息分析学,结合临床.....

                详情

                TCR-T

                T淋巴细胞是通过其表面特异性识别肿瘤抗原的T细胞受体(T Cell Receptor, TCR)来实现对肿瘤细胞的靶向识别.....

                详情

                科研合作

                联系电话:(上海)021-61049928

                (深圳)0755-86960876

                邮  箱:hryz@shhryz.com

                详情